Case of “Tangning Tongluo Tablets” Exempted from Phase II Clinical Trials Shared
On November 21, 2024, the 15th special report lecture of the year, hosted by the Guangdong-Macao In-Depth Cooperation Zone in Hengqin of Healthy and Biomedical Industry Association, was successfully held in the 3rd-floor library of the Scientific Research Headquarters Building of the Traditional Chinese Medicine Science and Technology Industrial Park of Co-operation between Guangdong and Macao. The lecture specially invited Xia Wen, Chairman of Beletalent (ZHUHAI) Pharmaceutical Co., Ltd.(hereinafter referred to as Beletalent), a vice-chairman unit of the association, and Director of Research and Development at Guizhou Bailing, as the guest speaker to share a case study on the new drug “Tangning Tongluo Tablets,” which was exempted from Phase II clinical trials.
Xia Wen detailed the research and development journey of the innovative traditional Chinese medicine “Tangning Tongluo Tablets,” covering aspects such as the exploration and research of the drug’s efficacy and mechanism of action, the results of toxicological studies, and the process of obtaining human experience. It can be said that “Tangning Tongluo Tablets,” as an innovative drug for the treatment of diabetic retinopathy, has a development process that condenses the efforts of scientific researchers over many years. From early drug discovery to pharmaceutical and pharmacological toxicological research, medical institution preparation clinical application, and the accumulation of human experience, each link is closely connected and thought-provoking.
Xia Wen, Director of Research and Development at Guizhou Bailing and Chairman of Beletalent, pointed out that the approval for Tangning Tongluo Tablets to directly enter Phase III clinical trials is a milestone for the company in continuously advancing scientific research innovation and the transformation of research outcomes. The company will continue to accelerate the process to bring Tangning Tongluo Tablets to market as a new drug at an early date, contributing to the development of traditional Chinese medicine in the cooperation zone.
The lecture attracted many research and development personnel from enterprises to participate in learning and exchange, they also engaged in discussions with Xia Wen about the process of exempting phase II clinical trials and applying for phase III clinical trials for “Tangning Tongluo tablets”. Participants expressed that they gained a lot from the event.
Currently, “Tangning Tongluo Tablets” is actively preparing for Phase III clinical trials, which will be a comprehensive test of the drug’s efficacy and safety in a larger population of diabetic patients. If the Phase III clinical trials are successful, “Tangning Tongluo Tablets” is expected to be officially approved for marketing, providing a new and more effective treatment option for a wide range of diabetic patients. This could potentially rewrite the pattern of diabetes treatment, bringing more hope and well-being to patients.
The advent of “Tangning Tongluo Tablets” has injected new vitality into the field of diabetes treatment, and its exemption from Phase II clinical trials further highlights the importance of combining scientific innovation with rigorous assessment. We look forward to this new drug achieving outstanding results in the upcoming Phase III clinical trials, and hope that it will soon be able to safeguard the health of diabetic patients.
